{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:21:23Z","timestamp":1707524483907},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,7]]},"DOI":"10.7759\/cureus.21985","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T15:34:06Z","timestamp":1644248046000},"source":"Crossref","is-referenced-by-count":1,"title":["Hunter Syndrome: The Phenotype of a Rare Storage Disease"],"prefix":"10.7759","author":[{"given":"Rute","family":"Sousa Martins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arlindo","family":"Guimas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Orphanet. Mucopolysaccharidosis type 2. (2019). Accessed. December 5, 2021: https:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?lng=en&Expert=580."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.2020.01011","article-title":"A basic understanding of mucopolysaccharidosis: incidence, clinical features, diagnosis, and management","volume":"9","author":"Zhou J","year":"2020","unstructured":"Zhou J, Lin J, Leung WT, Wang L. A basic understanding of mucopolysaccharidosis: incidence, clinical features, diagnosis, and management. Intractable Rare Dis Res. 2020, 9:1-9. 10.5582\/irdr.2020.01011","journal-title":"Intractable Rare Dis Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/bs.accb.2019.09.001","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): clinical and biochemical aspects of the disease and approaches to its diagnosis and treatment","volume":"77","author":"Mohamed S","year":"2020","unstructured":"Mohamed S, He QQ, Singh AA, Ferro V. Mucopolysaccharidosis type II (Hunter syndrome): clinical and biochemical aspects of the disease and approaches to its diagnosis and treatment. Adv Carbohydr Chem Biochem. 2020, 77:71-117. 10.1016\/bs.accb.2019.09.001","journal-title":"Adv Carbohydr Chem Biochem"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith JE","year":"2008","unstructured":"Wraith JE, Scarpa M, Beck M, et al.. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008, 167:267-77. 10.1007\/s00431-007-0635-4","journal-title":"Eur J Pediatr"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041258","article-title":"Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment","volume":"21","author":"D'Avanzo F","year":"2020","unstructured":"D'Avanzo F, Rigon L, Zanetti A, Tomanin R. Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment. Int J Mol Sci. 2020, 21:1258. 10.3390\/ijms21041258","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-72","article-title":"Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease","volume":"6","author":"Scarpa M","year":"2011","unstructured":"Scarpa M, Alm\u00e1ssy Z, Beck M, et al.. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis. 2011, 6:72. 10.1186\/1750-1172-6-72","journal-title":"Orphanet J Rare Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22157888","article-title":"Differences in MPS I and MPS II disease manifestations","volume":"22","author":"Hampe CS","year":"2021","unstructured":"Hampe CS, Yund BD, Orchard PJ, Lund TC, Wesley J, McIvor RS. Differences in MPS I and MPS II disease manifestations. Int J Mol Sci. 2021, 22:7888. 10.3390\/ijms22157888","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-020-0909-z","article-title":"Treatment of mucopolysaccharidosis type II (Hunter syndrome): a Delphi derived practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"22","author":"McBride KL","year":"2020","unstructured":"McBride KL, Berry SA, Braverman N. Treatment of mucopolysaccharidosis type II (Hunter syndrome): a Delphi derived practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2020, 22:1735-42. 10.1038\/s41436-020-0909-z","journal-title":"Genet Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1590\/S1415-47572010005000093","article-title":"Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment","volume":"33","author":"Giugliani R","year":"2010","unstructured":"Giugliani R, Federhen A, Rojas MV, et al.. Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment. Genet Mol Biol. 2010, 33:589-604. 10.1590\/S1415-47572010005000093","journal-title":"Genet Mol Biol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2007.00212.x","article-title":"A clinical study of 77 patients with mucopolysaccharidosis type II","volume":"96","author":"Schwartz IV","year":"2007","unstructured":"Schwartz IV, Ribeiro MG, Mota JG, et al.. A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatr. 2007, 96:63-70. 10.1111\/j.1651-2227.2007.00212.x","journal-title":"Acta Paediatr"},{"key":"ref11","article-title":"Mucopolysaccharidosis type II, Hunter's syndrome","volume":"12","author":"Tylki-Szyma\u0144ska A","year":"2014","unstructured":"Tylki-Szyma\u0144ska A. Mucopolysaccharidosis type II, Hunter's syndrome. Pediatr Endocrinol Rev. 2014, 12:107-13.","journal-title":"Pediatr Endocrinol Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2016.05.017","article-title":"Unique medical issues in adult patients with mucopolysaccharidoses","volume":"34","author":"Mitchell J","year":"2016","unstructured":"Mitchell J, Berger KI, Borgo A, et al.. Unique medical issues in adult patients with mucopolysaccharidoses. Eur J Intern Med. 2016, 34:2-10. 10.1016\/j.ejim.2016.05.017","journal-title":"Eur J Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2004.10.009","article-title":"Mucopolysaccharidosis type II in females: case report and review of literature","volume":"32","author":"Tuschl K","year":"2005","unstructured":"Tuschl K, Gal A, Paschke E, Kircher S, Bodamer OA. Mucopolysaccharidosis type II in females: case report and review of literature. Pediatr Neurol. 2005, 32:270-2. 10.1016\/j.pediatrneurol.2004.10.009","journal-title":"Pediatr Neurol"},{"key":"ref14","article-title":"A rare disease in two brothers","volume":"10","author":"Hunter C","year":"1917","unstructured":"Hunter C. A rare disease in two brothers. Proc R Soc Med. 1917, 10:104-16.","journal-title":"Proc R Soc Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620x.79b4.7547","article-title":"Carpal tunnel syndrome in the mucopolysaccharidoses and mucolipidoses","volume":"79","author":"Haddad FS","year":"1997","unstructured":"Haddad FS, Jones DH, Vellodi A, Kane N, Pitt MC. Carpal tunnel syndrome in the mucopolysaccharidoses and mucolipidoses. J Bone Joint Surg Br. 1997, 79:576-82. 10.1302\/0301-620x.79b4.7547","journal-title":"J Bone Joint Surg Br"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-011-1606-3","article-title":"The role of enzyme replacement therapy in severe Hunter syndrome\u2014an expert panel consensus","volume":"171","author":"Muenzer J","year":"2012","unstructured":"Muenzer J, Bodamer O, Burton B, et al.. The role of enzyme replacement therapy in severe Hunter syndrome\u2014an expert panel consensus. Eur J Pediatr. 2012, 171:181-8. 10.1007\/s00431-011-1606-3","journal-title":"Eur J Pediatr"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/164_2019_263","article-title":"Current and emerging therapies for mucopolysaccharidoses","volume":"261","author":"Lagler FB","year":"2020","unstructured":"Lagler FB. Current and emerging therapies for mucopolysaccharidoses. Handb Exp Pharmacol. 2020, 261:39-56. 10.1007\/164_2019_263","journal-title":"Handb Exp Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/84581-hunter-syndrome-the-phenotype-of-a-rare-storage-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:44:24Z","timestamp":1707507864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/84581-hunter-syndrome-the-phenotype-of-a-rare-storage-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,7]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.21985","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,7]]}}}